Comparing Praluent vs Zepbound
| Praluent (alirocumab) | Zepbound (tirzepatide) |
|
|---|
| Praluent (alirocumab) | Zepbound (tirzepatide) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Praluent is a PCSK9 inhibitor that may be used to reduce LDL-C levels in people with primary hyperlipidemia, genetically high cholesterol, or to reduce the risk of a heart attack, stroke, or... View more |
Prescription only
Prescribed for Weight Loss (Obesity/Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome. Zepbound may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Praluent (alirocumab) | More about Zepbound (tirzepatide) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Praluent has an average rating of 6.3 out of 10 from a total of 306 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 31% reported a negative effect. |
Zepbound has an average rating of 8.9 out of 10 from a total of 305 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 1% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Praluent side effects |
View all Zepbound side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Praluent prices |
View all Zepbound prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
Other tirzepatide brands include: Mounjaro | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
480 hours |
120 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 2 drugs are known to interact with Praluent:
|
A total of 414 drugs are known to interact with Zepbound:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||
| Disease Interactions | |||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||
| First Approval Date | |||||||||||||||||
|
July 24, 2015 |
N/A |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.